(NASDAQ: ELTX) Elicio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.04%.
Elicio Therapeutics's earnings in 2026 is -$37,841,000.On average, 6 Wall Street analysts forecast ELTX's earnings for 2026 to be -$53,078,889, with the lowest ELTX earnings forecast at -$54,088,113, and the highest ELTX earnings forecast at -$50,224,677. On average, 5 Wall Street analysts forecast ELTX's earnings for 2027 to be -$65,089,709, with the lowest ELTX earnings forecast at -$77,268,733, and the highest ELTX earnings forecast at -$42,497,803.
In 2028, ELTX is forecast to generate -$72,380,303 in earnings, with the lowest earnings forecast at -$84,995,606 and the highest earnings forecast at -$57,951,550.